<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Stock Blog Hub &#187; CHMP</title>
	<atom:link href="http://www.stockbloghub.com/tag/chmp/feed" rel="self" type="application/rss+xml" />
	<link>http://www.stockbloghub.com</link>
	<description>Start Your Investing Research Here!</description>
	<lastBuildDate>Tue, 22 May 2012 18:53:06 +0000</lastBuildDate>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.3.2</generator>
		<item>
		<title>(OPTR) Optimer Pharmaceuticals Dificlir Cleared in European Union</title>
		<link>http://www.stockbloghub.com/2011/12/15/optr-optimer-pharmaceuticals-dificlir-cleared-in-european-union/88596</link>
		<comments>http://www.stockbloghub.com/2011/12/15/optr-optimer-pharmaceuticals-dificlir-cleared-in-european-union/88596#comments</comments>
		<pubDate>Thu, 15 Dec 2011 10:00:22 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[CBST]]></category>
		<category><![CDATA[CDI]]></category>
		<category><![CDATA[CDI Corporation]]></category>
		<category><![CDATA[Champion Industries Inc]]></category>
		<category><![CDATA[CHMP]]></category>
		<category><![CDATA[Cubist Pharmaceuticals Inc.]]></category>
		<category><![CDATA[EU]]></category>
		<category><![CDATA[Optimer Pharmaceuticals Inc]]></category>
		<category><![CDATA[OPTR]]></category>
		<category><![CDATA[ViroPharma Inc]]></category>
		<category><![CDATA[VPHM]]></category>
		<category><![CDATA[WisdomTree Dreyfus Euro]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=88596</guid>
		<description><![CDATA[Optimer Pharmaceuticals, Inc. (OPTR) and partner Astellas Pharma recently announced that their antibiotic Dificlir received approval in the European Union (EU), not belying expectations. The European Medicines Agency (EMA) cleared Dificlir for the treatment of clostridium difficile-associated diarrhea (CDAD) also known as clostridium difficile infection (CDI). CDAD is the most common nosocomial or hospital-acquired diarrhea and is a significant malaise in hospitals and nursing home facilities. The EU approval does not surprise us since in September this year Dificlir received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) of the EMA. Dificlir is already marketed as Dificid in the US for CDAD in partnership with Cubist Pharmaceuticals, Inc. (CBST). The European regulatory body’s decision was based on data from two late stage studies which showed ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/12/15/optr-optimer-pharmaceuticals-dificlir-cleared-in-european-union/88596/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(VPHM) ViroPharma Going Strong</title>
		<link>http://www.stockbloghub.com/2011/11/04/vphm-viropharma-going-strong/86191</link>
		<comments>http://www.stockbloghub.com/2011/11/04/vphm-viropharma-going-strong/86191#comments</comments>
		<pubDate>Fri, 04 Nov 2011 18:37:45 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Champion Industries Inc]]></category>
		<category><![CDATA[CHMP]]></category>
		<category><![CDATA[EU]]></category>
		<category><![CDATA[HAE]]></category>
		<category><![CDATA[Haemonetics Corporation]]></category>
		<category><![CDATA[HALO]]></category>
		<category><![CDATA[Halozyme Therapeutics Inc]]></category>
		<category><![CDATA[Optimer Pharmaceuticals Inc]]></category>
		<category><![CDATA[OPTR]]></category>
		<category><![CDATA[ViroPharma Inc]]></category>
		<category><![CDATA[VPHM]]></category>
		<category><![CDATA[WisdomTree Dreyfus Euro]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=86191</guid>
		<description><![CDATA[ViroPharma Inc. (VPHM) posted third quarter 2011 earnings (including special items) of 35 cents per share, surpassing the Zacks Consensus Estimate of 33 cents, but lower than the year-ago figure of 45 cents. Excluding special items, but including stock based compensation expense, earnings came in at 52 cents per share for the third quarter, reflecting an increase of 8.3%. Higher revenues and lower share count helped boost earnings. Revenues Higher sales from Cinryze helped improve quarterly revenues to $143.0 million, from $117.8 million reported in the year-ago quarter. Revenues also beat the Zacks Consensus Estimate of $131.0 million. Cinryze sales increased 33.2% to $65.4 million during the reported quarter, and Vancocin sales came in at $76.6 million, reflecting an increase of 13.3%. While the increase in Cinryze sales was due ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/11/04/vphm-viropharma-going-strong/86191/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(NVS) Novartis Drug Cleared in European Union for SEGA</title>
		<link>http://www.stockbloghub.com/2011/09/20/nvs-novartis-drug-cleared-in-eu-for-sega/83127</link>
		<comments>http://www.stockbloghub.com/2011/09/20/nvs-novartis-drug-cleared-in-eu-for-sega/83127#comments</comments>
		<pubDate>Tue, 20 Sep 2011 19:12:00 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Champion Industries Inc]]></category>
		<category><![CDATA[CHMP]]></category>
		<category><![CDATA[EU]]></category>
		<category><![CDATA[HCC]]></category>
		<category><![CDATA[HCC Insurance Holdings Inc.]]></category>
		<category><![CDATA[Novartis AG]]></category>
		<category><![CDATA[NVS]]></category>
		<category><![CDATA[ONXX]]></category>
		<category><![CDATA[Onyx Pharmaceuticals Inc]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[Tenaris SA]]></category>
		<category><![CDATA[TS]]></category>
		<category><![CDATA[WisdomTree Dreyfus Euro]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=83127</guid>
		<description><![CDATA[Novartis (NVS) recently received a boost when its drug Votubia was approved for the treatment of subependymal giant cell astrocytomas (SEGA), a benign brain tumor associated with tuberous sclerosis (TS) in the European Union (EU). For the first time ever will such a medication be available in this region for the treatment of this challenging disease. Votubia is already marketed in the US under the trade name Afinitor for the disease. It is also approved in Switzerland, Brazil, Colombia, Guatemala, the Philippines and South Korea to treat SEGA associated with TS. Earlier in June this year, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) recommended approval of Votubia for the indication. The recommendation was based on data from a mid-stage study, which showed ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/09/20/nvs-novartis-drug-cleared-in-eu-for-sega/83127/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(VRTX) Vertex Pharmaceuticals Reports Positive Data</title>
		<link>http://www.stockbloghub.com/2011/09/12/vrtx-vertex-pharmaceuticals-reports-positive-data/82979</link>
		<comments>http://www.stockbloghub.com/2011/09/12/vrtx-vertex-pharmaceuticals-reports-positive-data/82979#comments</comments>
		<pubDate>Mon, 12 Sep 2011 17:19:46 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[BID]]></category>
		<category><![CDATA[Champion Industries Inc]]></category>
		<category><![CDATA[CHMP]]></category>
		<category><![CDATA[EU]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[MAA]]></category>
		<category><![CDATA[Mid-America Apartment Communities Inc]]></category>
		<category><![CDATA[RA]]></category>
		<category><![CDATA[Railamerica Inc]]></category>
		<category><![CDATA[Sotheby's]]></category>
		<category><![CDATA[Vertex Pharmaceuticals Incorporated]]></category>
		<category><![CDATA[VRTX]]></category>
		<category><![CDATA[WisdomTree Dreyfus Euro]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=82979</guid>
		<description><![CDATA[Vertex Pharmaceuticals Inc. (VRTX) reported positive data from a mid-stage trial on VX-509, which is being studied for the treatment of moderate to severe rheumatoid arthritis (RA). The 12-week study, which evaluated four doses of the candidate, met both the primary endpoints. Data from the two highest dose (100 mg and 150 mg) treatment arms demonstrated significant improvement in the proportion of people who achieved at least a 20% improvement in the signs and symptoms of RA (ACR20), and a statistically significant improvement from baseline in Disease Activity Score 28 (DAS28), compared to placebo. The study also met the secondary endpoints (ACR50 and ACR70) of achieving statistically significant responses compared to placebo. On the basis of the data from the phase IIa study, Vertex Pharma plans to initiate a six-month ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/09/12/vrtx-vertex-pharmaceuticals-reports-positive-data/82979/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(NVS) Novartis Neuroendocrine Tumors Drug Cleared in European Union</title>
		<link>http://www.stockbloghub.com/2011/09/11/nvs-novartis-neuroendocrine-tumors-drug-cleared-in-european-union/82655</link>
		<comments>http://www.stockbloghub.com/2011/09/11/nvs-novartis-neuroendocrine-tumors-drug-cleared-in-european-union/82655#comments</comments>
		<pubDate>Sun, 11 Sep 2011 19:54:01 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[AI]]></category>
		<category><![CDATA[Arlington Asset Investment Corporation]]></category>
		<category><![CDATA[Champion Industries Inc]]></category>
		<category><![CDATA[CHMP]]></category>
		<category><![CDATA[EU]]></category>
		<category><![CDATA[HCC]]></category>
		<category><![CDATA[HCC Insurance Holdings Inc.]]></category>
		<category><![CDATA[Novartis AG]]></category>
		<category><![CDATA[NVS]]></category>
		<category><![CDATA[ONXX]]></category>
		<category><![CDATA[Onyx Pharmaceuticals Inc]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[Stephan Company]]></category>
		<category><![CDATA[Tenaris SA]]></category>
		<category><![CDATA[TS]]></category>
		<category><![CDATA[TSC]]></category>
		<category><![CDATA[WisdomTree Dreyfus Euro]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=82655</guid>
		<description><![CDATA[Novartis’(NVS) drug Afinitor was recently approved in the European Union (EU) for the treatment of patients with advanced neuroendocrine tumors (NET) of pancreatic origin with progressive disease. The drug is already approved in the US for the indication. The approval was based on the RADIANT-3 trial which demonstrated that Afinitor led to a statistically significant improvement in progression-free survival versus placebo. The number of months of survival without the disease progressing was 11 months for a patient treated with Afinitor versus 4.6 months for a patient on placebo. Afinitor is currently marketed for the treatment of advanced renal cell carcinoma (kidney cancer) after an anti-VEGF therapy like Roche’s (RHHBY) Avastin, Pfizer’s (PFE) Sutent or Onyx Pharmaceuticals’(ONXX) Nexavar in the US and EU. In June this year, the Committee for Medicinal ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/09/11/nvs-novartis-neuroendocrine-tumors-drug-cleared-in-european-union/82655/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(CTIC) Cell Therapeutics Quarterly Earnings Lag &#8211; Company Pares Loss</title>
		<link>http://www.stockbloghub.com/2011/08/03/ctic-cell-therapeutics-quarterly-earnings-lag-company-pares-loss/80335</link>
		<comments>http://www.stockbloghub.com/2011/08/03/ctic-cell-therapeutics-quarterly-earnings-lag-company-pares-loss/80335#comments</comments>
		<pubDate>Wed, 03 Aug 2011 15:45:32 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Cell Therapeutics Inc]]></category>
		<category><![CDATA[Champion Industries Inc]]></category>
		<category><![CDATA[Charles River Laboratories International Inc]]></category>
		<category><![CDATA[CHMP]]></category>
		<category><![CDATA[CRL]]></category>
		<category><![CDATA[CTIC]]></category>
		<category><![CDATA[EU]]></category>
		<category><![CDATA[MDS]]></category>
		<category><![CDATA[Midas Inc.]]></category>
		<category><![CDATA[WisdomTree Dreyfus Euro]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=80335</guid>
		<description><![CDATA[Cell Therapeutics (CTIC) suffered a net loss of 14 cents per share in the second quarter of 2011, compared with a net loss of 46 cents (excluding special items) per share in the year-ago quarter. The narrower loss per share in the reported quarter was due to lower operating expenses and lower deemed dividend paid to preferred shareholders. The Zacks Consensus Estimate for the reported quarter was a loss of 12 cents per share. Cell Therapeutics did not generate any revenue during the reported quarter versus $0.029 million in the second quarter of 2010. Total operating expense in the quarter declined 15% to $16.9 million. Pipeline Update In June this year, Cell Therapeutics met with the Division of Oncology Drug Products (the DODP) of the US Food and Drug Administration ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/08/03/ctic-cell-therapeutics-quarterly-earnings-lag-company-pares-loss/80335/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(VPHM) ViroPharma Quarterly Earnings Report Misses Due to Higher Expenses</title>
		<link>http://www.stockbloghub.com/2011/08/03/vphm-viropharma-quarterly-earnings-report-misses-due-to-higher-expenses/80406</link>
		<comments>http://www.stockbloghub.com/2011/08/03/vphm-viropharma-quarterly-earnings-report-misses-due-to-higher-expenses/80406#comments</comments>
		<pubDate>Wed, 03 Aug 2011 15:34:07 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Champion Industries Inc]]></category>
		<category><![CDATA[CHMP]]></category>
		<category><![CDATA[EC]]></category>
		<category><![CDATA[Ecopetrol Sa]]></category>
		<category><![CDATA[EU]]></category>
		<category><![CDATA[HAE]]></category>
		<category><![CDATA[Haemonetics Corporation]]></category>
		<category><![CDATA[HALO]]></category>
		<category><![CDATA[Halozyme Therapeutics Inc]]></category>
		<category><![CDATA[Optimer Pharmaceuticals Inc]]></category>
		<category><![CDATA[OPTR]]></category>
		<category><![CDATA[ViroPharma Inc]]></category>
		<category><![CDATA[VPHM]]></category>
		<category><![CDATA[WisdomTree Dreyfus Euro]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=80406</guid>
		<description><![CDATA[ViroPharma Inc. (VPHM) posted second quarter fiscal 2011 earnings of 36 cents per share, missing the Zacks Consensus Estimate by 3 cents and the year-ago figure by a penny. Despite higher revenues, earnings bore the brunt of increased operating expenses. Revenues Higher sales from Cinryze boosted the quarterly revenues from $109.0 million in the year-ago quarter to $128.8 million. However, revenues fell shy of the Zacks Consensus Estimate of $131.0 million. Cinryze sales increased 55.1% to $62.5 million during the reported quarter, while Vancocin sales came in at $65.2 million, reflecting a slide of 4.7%. The increase in Cinryze sales was due to higher patient demand. On the other hand, Vancocin sales were negatively impacted by declining volume, partly offset by price rise. Other Details Research and development (R&#38;D) expenses ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/08/03/vphm-viropharma-quarterly-earnings-report-misses-due-to-higher-expenses/80406/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(VRTX) Vertex Pharmaceuticals Loss Reduced by Incivek</title>
		<link>http://www.stockbloghub.com/2011/08/01/vrtx-vertex-pharmaceuticals-loss-reduced-by-incivek/80310</link>
		<comments>http://www.stockbloghub.com/2011/08/01/vrtx-vertex-pharmaceuticals-loss-reduced-by-incivek/80310#comments</comments>
		<pubDate>Mon, 01 Aug 2011 16:40:42 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[CF]]></category>
		<category><![CDATA[CF Industries Holdings Inc.]]></category>
		<category><![CDATA[Champion Industries Inc]]></category>
		<category><![CDATA[CHMP]]></category>
		<category><![CDATA[EU]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[MAA]]></category>
		<category><![CDATA[Mid-America Apartment Communities Inc]]></category>
		<category><![CDATA[Vertex Pharmaceuticals Incorporated]]></category>
		<category><![CDATA[VRTX]]></category>
		<category><![CDATA[WisdomTree Dreyfus Euro]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=80310</guid>
		<description><![CDATA[Vertex Pharmaceuticals Inc. (VRTX) posted second quarter 2011 loss (including stock-based compensation expense) of 82 cents per share, narrower than the Zacks Consensus Estimate of 93 cents and the year-ago loss of 83 cents. Increased revenues from the sale of hepatitis C virus (HCV) candidate, Incivek (telaprevir) helped reduce the loss. Revenues Riding on the strong sales of Incivek, which was launched during the quarter, total revenue soared 262% to $114.4 million, surpassing the Zacks Consensus Estimate of $54 million. Vertex Pharma’s first quarter revenues consisted of revenue earned from the sale of Incivek ($74.5 million), royalty revenue (up 37.8% to $10.0 million) and collaborative revenue (up 22.7% to $30.0 million). The company receives royalty from GlaxoSmithKline plc (GSK) on sales of Lexiva, a HIV protease inhibitor. Collaborative revenue consists ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/08/01/vrtx-vertex-pharmaceuticals-loss-reduced-by-incivek/80310/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(NVS) Novartis Presents Afinitor Data</title>
		<link>http://www.stockbloghub.com/2011/07/12/nvs-novartis-presents-afinitor-data/78847</link>
		<comments>http://www.stockbloghub.com/2011/07/12/nvs-novartis-presents-afinitor-data/78847#comments</comments>
		<pubDate>Tue, 12 Jul 2011 16:58:10 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Champion Industries Inc]]></category>
		<category><![CDATA[CHMP]]></category>
		<category><![CDATA[HCC]]></category>
		<category><![CDATA[HCC Insurance Holdings Inc.]]></category>
		<category><![CDATA[Novartis AG]]></category>
		<category><![CDATA[NVS]]></category>
		<category><![CDATA[ONXX]]></category>
		<category><![CDATA[Onyx Pharmaceuticals Inc]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[Stephan Company]]></category>
		<category><![CDATA[Tenaris SA]]></category>
		<category><![CDATA[TS]]></category>
		<category><![CDATA[TSC]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=78847</guid>
		<description><![CDATA[Recently, Novartis (NVS) presented data from a late-stage study (EXIST-1) of its cancer drug Afinitor (everolimus). The randomized, placebo-controlled, double-blind, multicenter study evaluated the safety and effectiveness of the drug compared to placebo for treating patients with subependymal giant cell astrocytomas (SEGAs) coupled with tuberous sclerosis (TS). Results from the study were presented at the International tuberous sclerosis complex (TSC) Research Conference in the US. The study revealed that treatment with Afinitor caused a 50% or more reduction in SEGA tumor size in 35% of the patients. However, no such reduction was observed in the placebo arm. SEGA refers to a benign brain tumor associated with tuberous sclerosis. TSC, which is associated with multiple disorders such as seizures, swelling in the brain, developmental delays and skin lesions, affects approximately one ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/07/12/nvs-novartis-presents-afinitor-data/78847/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(NVS) Novartis AG&#8217;s Afinitor Impresses Again</title>
		<link>http://www.stockbloghub.com/2011/07/07/nvs-novartis-ags-afinitor-impresses-again/78554</link>
		<comments>http://www.stockbloghub.com/2011/07/07/nvs-novartis-ags-afinitor-impresses-again/78554#comments</comments>
		<pubDate>Thu, 07 Jul 2011 17:02:12 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Champion Industries Inc]]></category>
		<category><![CDATA[CHMP]]></category>
		<category><![CDATA[EU]]></category>
		<category><![CDATA[HCC]]></category>
		<category><![CDATA[HCC Insurance Holdings Inc.]]></category>
		<category><![CDATA[Novartis AG]]></category>
		<category><![CDATA[NVS]]></category>
		<category><![CDATA[ONXX]]></category>
		<category><![CDATA[Onyx Pharmaceuticals Inc]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[PFS]]></category>
		<category><![CDATA[Provident Financial Services Inc]]></category>
		<category><![CDATA[Stephan Company]]></category>
		<category><![CDATA[Tenaris SA]]></category>
		<category><![CDATA[TS]]></category>
		<category><![CDATA[TSC]]></category>
		<category><![CDATA[WisdomTree Dreyfus Euro]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=78554</guid>
		<description><![CDATA[It seems Novartis AG’s (NVS) breast cancer drug, Afinitor (everolimus), is getting into a habit of delivering positive news. Right after the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) recommended approval of Afinitor last week for the treatment of subependymal giant cell astrocytomas (SEGA), the drug impressed again this week with positive interim results from a pivotal late-stage trial (BOLERO-2). BOLERO-2 evaluated Afinitor in combination with exemestane versus placebo plus exemestane in postmenopausal women with estrogen receptor-positive locally-advanced breast cancer, whose disease progressed, despite treatment with the nonsteroidal aromatase inhibitors letrozole or anastrozole. The trial results demonstrated that patients with advanced breast cancer who were dosed Afinitor in combination with exemestane, experienced significantly extended progression-free survival (PFS), as compared to patients who received ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/07/07/nvs-novartis-ags-afinitor-impresses-again/78554/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(NVS) Novartis AG Afinitor Backed in EU</title>
		<link>http://www.stockbloghub.com/2011/06/29/nvs-novartis-ag-afinitor-backed-in-eu/77906</link>
		<comments>http://www.stockbloghub.com/2011/06/29/nvs-novartis-ag-afinitor-backed-in-eu/77906#comments</comments>
		<pubDate>Wed, 29 Jun 2011 20:55:05 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[AI]]></category>
		<category><![CDATA[Arlington Asset Investment Corporation]]></category>
		<category><![CDATA[Champion Industries Inc]]></category>
		<category><![CDATA[CHMP]]></category>
		<category><![CDATA[HCC]]></category>
		<category><![CDATA[HCC Insurance Holdings Inc.]]></category>
		<category><![CDATA[Novartis AG]]></category>
		<category><![CDATA[NVS]]></category>
		<category><![CDATA[ONXX]]></category>
		<category><![CDATA[Onyx Pharmaceuticals Inc]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[Stephan Company]]></category>
		<category><![CDATA[Tenaris SA]]></category>
		<category><![CDATA[TS]]></category>
		<category><![CDATA[TSC]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=77906</guid>
		<description><![CDATA[Novartis AG (NVS) received a boost recently when the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) recommended approval of its drug Afinitor for the treatment of subependymal giant cell astrocytomas (SEGA), a benign brain tumor associated with tuberous sclerosis (TS), in the European Union. The European Commission is expected to give its decision within the next three months. The drug will be marketed in the EU in the trade name of Votubia and will be the first medicine in the region for the treatment of this challenging disease, if approved. It is already marketed in the US as Afinitor for the disease. It is also approved in Switzerland Brazil, Colombia, Guatemala, the Philippines and South Korea to treat SEGA associated with TS. Novartis ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/06/29/nvs-novartis-ag-afinitor-backed-in-eu/77906/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(AMGN) Amgen Drug Earns Positive Committee for Medicinal Products for Human Use Opinion</title>
		<link>http://www.stockbloghub.com/2011/06/29/amgn-amgen-drug-earns-positive-committee-for-medicinal-products-for-human-use-opinion/77581</link>
		<comments>http://www.stockbloghub.com/2011/06/29/amgn-amgen-drug-earns-positive-committee-for-medicinal-products-for-human-use-opinion/77581#comments</comments>
		<pubDate>Wed, 29 Jun 2011 17:07:28 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Amgen Inc]]></category>
		<category><![CDATA[AMGN]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[Champion Industries Inc]]></category>
		<category><![CDATA[CHMP]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[LLY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=77581</guid>
		<description><![CDATA[Amgen (AMGN) recently announced that it received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) for a label expansion for its oncology product, Vectibix. Amgen is looking to gain EU approval for the use of Vectibix in patients with wild-type KRAS metastatic colorectal cancer (mCRC) as a first-line treatment in combination with FOLFOX and second-line treatment in combination with FOLFIRI in patients who have received first-line fluoropyrimidine-based chemotherapy (excluding irinotecan). The CHMP had previously adopted a negative opinion regarding Amgen’s marketing authorization application for Vectibix’ label expansion. Amgen filed an appeal against the decision in March 2011 requesting the EMA to re-examine the CHMP’s opinion. With the CHMP now changing its view, a final decision from the European regulatory ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/06/29/amgn-amgen-drug-earns-positive-committee-for-medicinal-products-for-human-use-opinion/77581/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(CHMP) ViroPharma&#8217;s Epilepsy Drug Recommended</title>
		<link>http://www.stockbloghub.com/2011/06/28/chmp-viropharmas-epilepsy-drug-recommended/77702</link>
		<comments>http://www.stockbloghub.com/2011/06/28/chmp-viropharmas-epilepsy-drug-recommended/77702#comments</comments>
		<pubDate>Tue, 28 Jun 2011 20:02:02 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Business Services]]></category>
		<category><![CDATA[Services]]></category>
		<category><![CDATA[AMR]]></category>
		<category><![CDATA[AMR Corporation]]></category>
		<category><![CDATA[Champion Industries Inc]]></category>
		<category><![CDATA[CHMP]]></category>
		<category><![CDATA[EC]]></category>
		<category><![CDATA[Ecopetrol Sa]]></category>
		<category><![CDATA[HAE]]></category>
		<category><![CDATA[Haemonetics Corporation]]></category>
		<category><![CDATA[HALO]]></category>
		<category><![CDATA[Halozyme Therapeutics Inc]]></category>
		<category><![CDATA[ViroPharma Inc]]></category>
		<category><![CDATA[VPHM]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=77702</guid>
		<description><![CDATA[The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) recently gave the go ahead to ViroPharma Inc.’s (VPHM) Buccolam (midazolam, oromucosal solution). The company is seeking approval for Buccolam to be used as a treatment for prolonged, acute, convulsive seizures in infants, toddlers, children and adolescents, from 3 months to less than 18 years. The European Commission’s (EC) decision on ViroPharma’s Pediatric Use Marketing Authorization (PUMA) for Buccolam is expected by the fourth quarter of 2011, which will also make the candidate the first product to gain approval under the centralized PUMA procedure. PUMA is a new type of centralized marketing authorization procedure for medicines that are developed specifically for children and may already be approved for other indications or routes of administration in adults. ViroPharma’s ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/06/28/chmp-viropharmas-epilepsy-drug-recommended/77702/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(VRTX) Vertex Pharmaceuticals Get Positive Data on Incivek</title>
		<link>http://www.stockbloghub.com/2011/06/24/vrtx-vertex-pharmaceuticals-get-positive-data-on-incivek/77386</link>
		<comments>http://www.stockbloghub.com/2011/06/24/vrtx-vertex-pharmaceuticals-get-positive-data-on-incivek/77386#comments</comments>
		<pubDate>Fri, 24 Jun 2011 20:36:58 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Champion Industries Inc]]></category>
		<category><![CDATA[CHMP]]></category>
		<category><![CDATA[GILD]]></category>
		<category><![CDATA[Gilead Sciences Inc]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[Merck & Company Inc]]></category>
		<category><![CDATA[MRK]]></category>
		<category><![CDATA[SVR]]></category>
		<category><![CDATA[Syniverse Holdings Inc.]]></category>
		<category><![CDATA[Vertex Pharmaceuticals Incorporated]]></category>
		<category><![CDATA[VRTX]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=77386</guid>
		<description><![CDATA[Vertex Pharmaceuticals Inc. (VRTX) recently reported data from two late stage trials – ADVANCE and REALIZE – on Incivek (telaprevir). The data were published in the June edition of the New England Journal of Medicine. The trial results demonstrated that when patients suffering from chronic hepatitis C (HCV) were given Incivek combination therapy, they experienced significant improvement in sustained viral response (SVR) rates, as compared to those who received pegylated-interferon and ribavirin alone. In the ADVANCE study, Incivek combination therapy demonstrated the aforesaid results in new patients, while the REALIZE study consisted of treatment-failed patients. We note that in the ADVANCE study, majority of the patients treated with Incivek combination therapy completed the treatment in 24 weeks, which is half the time needed in the pegylated-interferon and ribavirin arm. Further, ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/06/24/vrtx-vertex-pharmaceuticals-get-positive-data-on-incivek/77386/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(MS) Merck KGaA to Withdraw Multiple Sclerosis Drug</title>
		<link>http://www.stockbloghub.com/2011/06/23/ms-merck-kgaa-to-withdraw-multiple-sclerosis-drug/77278</link>
		<comments>http://www.stockbloghub.com/2011/06/23/ms-merck-kgaa-to-withdraw-multiple-sclerosis-drug/77278#comments</comments>
		<pubDate>Thu, 23 Jun 2011 20:03:18 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Diversified Investments]]></category>
		<category><![CDATA[Financial]]></category>
		<category><![CDATA[BIIB]]></category>
		<category><![CDATA[Biogen Idec Inc]]></category>
		<category><![CDATA[Champion Industries Inc]]></category>
		<category><![CDATA[CHMP]]></category>
		<category><![CDATA[Elan Corporation plc]]></category>
		<category><![CDATA[ELN]]></category>
		<category><![CDATA[Morgan Stanley]]></category>
		<category><![CDATA[MS]]></category>
		<category><![CDATA[TEVA]]></category>
		<category><![CDATA[Teva Pharmaceutical Industries Limited]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=77278</guid>
		<description><![CDATA[Merck KGaA (MKGAF) recently announced its plans to withdraw the regulatory applications filed with the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA), seeking approval to market cladribine as a treatment for relapsing-remitting multiple sclerosis (MS). This decision comes after Merck KGaA’s discussions with the FDA at the end-of-review meeting related to the new drug application (NDA) for cladribine. Merck KGaA believes that data from the ongoing clinical trials will not be sufficient to address the FDA’s requirements for approval. The company is of the view that to gain US and EU approval, it will have to conduct a new clinical trial program that would take several years to complete. Cladribine is currently marketed as Movectro in Australia and Russia for the treatment of relapsing-remitting MS. ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/06/23/ms-merck-kgaa-to-withdraw-multiple-sclerosis-drug/77278/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(AMLN) Amylin Pharmaceuticals, Partners Eli Lilly and Alkermes Learn Bydureon Gains EU Approval</title>
		<link>http://www.stockbloghub.com/2011/06/22/amln-amylin-pharmaceuticals-partners-eli-lilly-and-alkermes-learn-bydureon-gains-eu-approval/77181</link>
		<comments>http://www.stockbloghub.com/2011/06/22/amln-amylin-pharmaceuticals-partners-eli-lilly-and-alkermes-learn-bydureon-gains-eu-approval/77181#comments</comments>
		<pubDate>Thu, 23 Jun 2011 01:06:34 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Alkermes Inc.]]></category>
		<category><![CDATA[ALKS]]></category>
		<category><![CDATA[AMLN]]></category>
		<category><![CDATA[Amylin Pharmaceuticals Inc]]></category>
		<category><![CDATA[Champion Industries Inc]]></category>
		<category><![CDATA[CHMP]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[LLY]]></category>
		<category><![CDATA[Novo Nordisk A-S]]></category>
		<category><![CDATA[NVO]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=77181</guid>
		<description><![CDATA[Amylin Pharmaceuticals, Inc. (AMLN) and its partners, Eli Lilly and Company (LLY), and Alkermes, Inc. (ALKS), recently received a boost with the European Commission granting marketing authorization to Bydureon (exenatide once-weekly) for the treatment of type II diabetes. Bydureon is the first once-weekly treatment to gain approval for type II diabetes. Approval was granted for use in combination with metformin, a sulfonylurea, a thiazolidinedione, metformin plus a sulfonylurea or metformin plus a thiazolidinedione. EU Approval Was Expected EU approval was expected as, earlier in April, Bydureon had received a positive opinion from the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP). While anticipated, the final approval of Bydureon, nevertheless, comes as a relief for Amylin which has recently been at the receiving end of a series ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/06/22/amln-amylin-pharmaceuticals-partners-eli-lilly-and-alkermes-learn-bydureon-gains-eu-approval/77181/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(BIIB) Biogen Idec and Partner Elan Announce EU Label Update for Tysabri</title>
		<link>http://www.stockbloghub.com/2011/06/22/biib-biogen-idec-and-partner-elan-announce-eu-label-update-for-tysabri/77127</link>
		<comments>http://www.stockbloghub.com/2011/06/22/biib-biogen-idec-and-partner-elan-announce-eu-label-update-for-tysabri/77127#comments</comments>
		<pubDate>Wed, 22 Jun 2011 19:16:11 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[BIIB]]></category>
		<category><![CDATA[Biogen Idec Inc]]></category>
		<category><![CDATA[Champion Industries Inc]]></category>
		<category><![CDATA[CHMP]]></category>
		<category><![CDATA[EC]]></category>
		<category><![CDATA[Ecopetrol Sa]]></category>
		<category><![CDATA[Elan Corporation plc]]></category>
		<category><![CDATA[ELN]]></category>
		<category><![CDATA[EU]]></category>
		<category><![CDATA[Morgan Stanley]]></category>
		<category><![CDATA[MS]]></category>
		<category><![CDATA[Novartis AG]]></category>
		<category><![CDATA[NVS]]></category>
		<category><![CDATA[PIMCO Municipal Income Fund II]]></category>
		<category><![CDATA[PML]]></category>
		<category><![CDATA[WisdomTree Dreyfus Euro]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=77127</guid>
		<description><![CDATA[Recently, Biogen Idec, Inc. (BIIB) and partner Elan Corporation (ELN) announced that the European Commission (EC) has approved an update to the label for their multiple sclerosis (MS) drug Tysabri (natalizumab) in the European Union (EU). The updated label includes anti-JC Virus antibody status as an additional factor that could help stratify the risk of progressive multifocal leukoencephalopathy (PML) occurring in patients treated with Tysabri. The EC’s decision for the label update does not surprise us as in April 2011 the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMEA) had backed the inclusion of the additional risk in the Tysabri label. The updated label in the EU will provide patients (treated with Tysabri) as well as doctors additional assistance in identifying the risk of ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/06/22/biib-biogen-idec-and-partner-elan-announce-eu-label-update-for-tysabri/77127/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(BMY) Bristol-Myers Squibb Company Gets Another Feather in its Cap</title>
		<link>http://www.stockbloghub.com/2011/06/17/bmy-bristol-myers-squibb-company-gets-another-feather-in-its-cap/76633</link>
		<comments>http://www.stockbloghub.com/2011/06/17/bmy-bristol-myers-squibb-company-gets-another-feather-in-its-cap/76633#comments</comments>
		<pubDate>Fri, 17 Jun 2011 14:42:11 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[AstraZeneca plc]]></category>
		<category><![CDATA[AZN]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[Champion Industries Inc]]></category>
		<category><![CDATA[CHMP]]></category>
		<category><![CDATA[EU]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>
		<category><![CDATA[WisdomTree Dreyfus Euro]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=76633</guid>
		<description><![CDATA[Bristol-Myers Squibb Company’s (BMY) product portfolio was boosted further when the US Food and Drug Administration (FDA) approved its drug Nulojix (belatacept) to prevent the rejection of transplanted kidneys in adults. We remind investors that Bristol-Myers has succeeded in getting the drug approved in the US for the indication in its second attempt. In the second quarter of 2010, the FDA issued a complete response letter in response to biologic license application (BLA) submitted by the pharma major for Nulojix , asking for additional information. Subsequently, Bristol-Myers submitted it. In December 2010, the agency had thereby announced that it would review the re-submitted application by June 15, 2011 (action date). The agency cleared the drug following the review thereby delivering a further boost to the company. We note that the ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/06/17/bmy-bristol-myers-squibb-company-gets-another-feather-in-its-cap/76633/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(VPHM) ViroPharma&#8217;s HAE Drug Gets EU Nod</title>
		<link>http://www.stockbloghub.com/2011/06/16/vphm-viropharmas-hae-drug-gets-eu-nod/76542</link>
		<comments>http://www.stockbloghub.com/2011/06/16/vphm-viropharmas-hae-drug-gets-eu-nod/76542#comments</comments>
		<pubDate>Thu, 16 Jun 2011 15:20:14 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[AMR]]></category>
		<category><![CDATA[AMR Corporation]]></category>
		<category><![CDATA[Champion Industries Inc]]></category>
		<category><![CDATA[CHMP]]></category>
		<category><![CDATA[EC]]></category>
		<category><![CDATA[Ecopetrol Sa]]></category>
		<category><![CDATA[HAE]]></category>
		<category><![CDATA[Haemonetics Corporation]]></category>
		<category><![CDATA[HALO]]></category>
		<category><![CDATA[Halozyme Therapeutics Inc]]></category>
		<category><![CDATA[ViroPharma Inc]]></category>
		<category><![CDATA[VPHM]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=76542</guid>
		<description><![CDATA[ViroPharma Inc. (VPHM) recently announced that the European Commission (EC) granted Centralized Marketing Authorization to Cinryze for the treatment of hereditary angioedema (HAE). The drug is indicated for the treatment of pre-procedure prevention of angioedema attacks in adults and adolescents with HAE, and routine prevention of angioedema attacks in adults and adolescents with severe and recurrent attacks of HAE, who are intolerant to or insufficiently protected by oral prevention treatments, or patients who are inadequately managed with repeated acute treatment. The EC’s approval of Cinryze does not come as a surprise, as in March the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) had recommended it. We note that in May, ViroPharma had entered into a global licensing deal with Halozyme Therapeutics, Inc. (HALO), ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/06/16/vphm-viropharmas-hae-drug-gets-eu-nod/76542/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ACOR) Acorda Therapeutics Gets Mixed Data on Ampyra</title>
		<link>http://www.stockbloghub.com/2011/06/16/acor-acorda-therapeutics-gets-mixed-data-on-ampyra/76214</link>
		<comments>http://www.stockbloghub.com/2011/06/16/acor-acorda-therapeutics-gets-mixed-data-on-ampyra/76214#comments</comments>
		<pubDate>Thu, 16 Jun 2011 14:45:22 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[ACOR]]></category>
		<category><![CDATA[Acorda Therapeutics Inc]]></category>
		<category><![CDATA[BIIB]]></category>
		<category><![CDATA[Biogen Idec Inc]]></category>
		<category><![CDATA[Champion Industries Inc]]></category>
		<category><![CDATA[CHMP]]></category>
		<category><![CDATA[Elan Corporation plc]]></category>
		<category><![CDATA[ELN]]></category>
		<category><![CDATA[EU]]></category>
		<category><![CDATA[Morgan Stanley]]></category>
		<category><![CDATA[MS]]></category>
		<category><![CDATA[WisdomTree Dreyfus Euro]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=76214</guid>
		<description><![CDATA[Acorda Therapeutics, Inc. (ACOR) recently reported an analysis of data on Ampyra (dalfampridine) at the Consortium of Multiple Sclerosis Centers (CMSC) annual meeting. The analysis demonstrated improvements in walking ability of patients on Ampyra as measured by patient self-report on the 12-Item Multiple Sclerosis Walking Scale (MSWS-12). The analysis comprised data from a phase II trial and two phase III trials of Ampyra. These data were a part of Acorda’s new drug application (NDA) submission to the US Food and Drug Administration (FDA) for the approval of the drug. At the CMSC meeting, another set of study data on Ampyra called – UTI (urinary tract infection) Incidence among MS Patients Treated with Dalfampridine 10 mg Twice Daily – was also presented. As the name suggests, the study evaluated the incidence ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/06/16/acor-acorda-therapeutics-gets-mixed-data-on-ampyra/76214/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(THRX) Theravance Analyst Maintains Neutral on Shares</title>
		<link>http://www.stockbloghub.com/2011/06/14/thrx-theravance-analyst-maintains-neutral-on-shares-2/76322</link>
		<comments>http://www.stockbloghub.com/2011/06/14/thrx-theravance-analyst-maintains-neutral-on-shares-2/76322#comments</comments>
		<pubDate>Wed, 15 Jun 2011 03:24:41 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[CBST]]></category>
		<category><![CDATA[Champion Industries Inc]]></category>
		<category><![CDATA[Charles River Laboratories International Inc]]></category>
		<category><![CDATA[CHMP]]></category>
		<category><![CDATA[CRL]]></category>
		<category><![CDATA[Cubist Pharmaceuticals Inc.]]></category>
		<category><![CDATA[Forest Laboratories Inc.]]></category>
		<category><![CDATA[FRX]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[HAP]]></category>
		<category><![CDATA[Market Vectors RVE Hard Assets Prod ETF]]></category>
		<category><![CDATA[Neenah Paper Inc.]]></category>
		<category><![CDATA[NP]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[Theravance Inc]]></category>
		<category><![CDATA[THRX]]></category>
		<category><![CDATA[ViroPharma Inc]]></category>
		<category><![CDATA[VPHM]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=76322</guid>
		<description><![CDATA[We have maintained our Neutral recommendation on Theravance, Inc. (THRX) with a target price of $24.00 per share following the announcement of first quarter 2011 financial results. Theravance’s first quarter 2011 loss per share of 28 cents was in line with the Zacks Consensus Estimate, but narrower than the year-ago loss of 35 cents per share. Revenues at Theravance increased 10% year over year to $6.3 million. An increase in royalty revenues from Vibativ sales in the reported quarter was attributable for both the jump in revenues and the narrower year-over-year loss per share. However, total revenue was below the Zacks Consensus Revenue Estimate of $7 million. Theravance has active collaborations with GlaxoSmithKline (GSK) for the Relovair, LAMA/LABA (also called 719/VI) and MABA programs. The Relovair program holds the biggest ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/06/14/thrx-theravance-analyst-maintains-neutral-on-shares-2/76322/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(THRX) Theravance Analyst Maintains Neutral Rating on Shares</title>
		<link>http://www.stockbloghub.com/2011/06/14/thrx-theravance-analyst-maintains-neutral-rating-on-shares/76253</link>
		<comments>http://www.stockbloghub.com/2011/06/14/thrx-theravance-analyst-maintains-neutral-rating-on-shares/76253#comments</comments>
		<pubDate>Tue, 14 Jun 2011 15:03:48 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[CBST]]></category>
		<category><![CDATA[Champion Industries Inc]]></category>
		<category><![CDATA[CHMP]]></category>
		<category><![CDATA[Cubist Pharmaceuticals Inc.]]></category>
		<category><![CDATA[Forest Laboratories Inc.]]></category>
		<category><![CDATA[FRX]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[HAP]]></category>
		<category><![CDATA[Market Vectors RVE Hard Assets Prod ETF]]></category>
		<category><![CDATA[Neenah Paper Inc.]]></category>
		<category><![CDATA[NP]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[Theravance Inc]]></category>
		<category><![CDATA[THRX]]></category>
		<category><![CDATA[ViroPharma Inc]]></category>
		<category><![CDATA[VPHM]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=76253</guid>
		<description><![CDATA[We have maintained our Neutral recommendation on Theravance, Inc. (THRX) with a target price of $24.00 per share following the announcement of first quarter 2011 financial results. Theravance’s first quarter 2011 loss per share of 28 cents was in line with the Zacks Consensus Estimate, but narrower than the year-ago loss of 35 cents per share. Revenues at Theravance increased 10% year over year to $6.3 million. An increase in royalty revenues from Vibativ sales in the reported quarter was attributable for both the jump in revenues and the narrower year-over-year loss per share. However, total revenue was below the Zacks Consensus Revenue Estimate of $7 million. Theravance has active collaborations with GlaxoSmithKline (GSK) for the Relovair, LAMA/LABA (also called 719/VI) and MABA programs. The Relovair program holds the biggest ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/06/14/thrx-theravance-analyst-maintains-neutral-rating-on-shares/76253/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ACOR) Acorda Therapeutics Reports Loss That Missed Expectations</title>
		<link>http://www.stockbloghub.com/2011/05/08/acor-acorda-therapeutics-reports-loss-that-missed-expectations/73532</link>
		<comments>http://www.stockbloghub.com/2011/05/08/acor-acorda-therapeutics-reports-loss-that-missed-expectations/73532#comments</comments>
		<pubDate>Sun, 08 May 2011 15:50:53 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[ACOR]]></category>
		<category><![CDATA[Acorda Therapeutics Inc]]></category>
		<category><![CDATA[BIIB]]></category>
		<category><![CDATA[Biogen Idec Inc]]></category>
		<category><![CDATA[Champion Industries Inc]]></category>
		<category><![CDATA[CHMP]]></category>
		<category><![CDATA[Elan Corporation plc]]></category>
		<category><![CDATA[ELN]]></category>
		<category><![CDATA[EU]]></category>
		<category><![CDATA[WisdomTree Dreyfus Euro]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=73532</guid>
		<description><![CDATA[Acorda Therapeutics Inc. (ACOR) posted a loss of 2 cents per share for the first quarter of fiscal 2011, compared with a loss of 56 cents in the year-ago period. The Zacks Consensus Earnings Estimate for the quarter was 18 cents per share. Despite increased revenues, higher operating expenses resulted in a loss during the quarter. Quarterly Details Quarterly revenues saw a whopping 245.3% increase to reach $61.3 million, with Ampyra sales exceeding expectations. However, revenues missed the Zacks Consensus Estimate of $65 million. Fourth quarter revenues comprised $58.9 million (up 282.9%) in product sales and $2.4 million (flat year over year) in license and royalty revenue. Sales of Ampyra, which was launched in March 2010, came in at $46.8 million. Ampyra, aimed at improving walking speed in multiple sclerosis ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/05/08/acor-acorda-therapeutics-reports-loss-that-missed-expectations/73532/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(NVS) Novartis Posts Solid First Quarter Sales</title>
		<link>http://www.stockbloghub.com/2011/04/27/nvs-novartis-posts-solid-first-quarter-sales/71906</link>
		<comments>http://www.stockbloghub.com/2011/04/27/nvs-novartis-posts-solid-first-quarter-sales/71906#comments</comments>
		<pubDate>Wed, 27 Apr 2011 17:54:34 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Champion Industries Inc]]></category>
		<category><![CDATA[CHMP]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[INCY]]></category>
		<category><![CDATA[Incyte Corporation]]></category>
		<category><![CDATA[LLY]]></category>
		<category><![CDATA[MF]]></category>
		<category><![CDATA[MF Global Ltd]]></category>
		<category><![CDATA[Novartis AG]]></category>
		<category><![CDATA[NVS]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=71906</guid>
		<description><![CDATA[Novartis (NVS) reported earnings per share of $1.41 for the first quarter of 2011, below the year-earlier earnings of $1.45 per share but well ahead of the Zacks Consensus Estimate of $1.31. The drop from the base period resulted from financing costs for the Alcon acquisition completed in April this year. An increase in the number of shares outstanding, in the quarter, following dilution from the merger also affected earnings. Also marring earnings were robust profits booked in 2009 from windfall sales of H1N1 flu vaccines that were not to be repeated in the current quarter. First quarter revenues were up a solid 16% over the prior year to $14.0 billion. Total revenues also edged past the Zacks Consensus Estimate of $13.4 billion, driven by strong performance of newly launched ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/04/27/nvs-novartis-posts-solid-first-quarter-sales/71906/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(BIIB) Biogen Idec Earnings Above Estimates on Multiple Sclerosis Drugs</title>
		<link>http://www.stockbloghub.com/2011/04/26/biib-biogen-idec-earnings-above-estimates-on-multiple-sclerosis-drugs/72234</link>
		<comments>http://www.stockbloghub.com/2011/04/26/biib-biogen-idec-earnings-above-estimates-on-multiple-sclerosis-drugs/72234#comments</comments>
		<pubDate>Tue, 26 Apr 2011 15:42:25 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[BIIB]]></category>
		<category><![CDATA[Biogen Idec Inc]]></category>
		<category><![CDATA[Champion Industries Inc]]></category>
		<category><![CDATA[CHMP]]></category>
		<category><![CDATA[Elan Corporation plc]]></category>
		<category><![CDATA[ELN]]></category>
		<category><![CDATA[Morgan Stanley]]></category>
		<category><![CDATA[MS]]></category>
		<category><![CDATA[Novartis AG]]></category>
		<category><![CDATA[NVS]]></category>
		<category><![CDATA[PIMCO Municipal Income Fund II]]></category>
		<category><![CDATA[PML]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>
		<category><![CDATA[TEVA]]></category>
		<category><![CDATA[Teva Pharmaceutical Industries Limited]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=72234</guid>
		<description><![CDATA[Biogen Idec (BIIB) reported first-quarter earnings per share of $1.42, 3 cents above the Zacks Consensus Estimate of $1.39 and well above the year-earlier figure of $1.04. Excluding the impact of stock-based compensation expense, first quarter 2011 earnings came in at $1.43 per share. Performance was boosted by higher multiple sclerosis (MS) drug revenues, lower costs and lower share count. Biogen has been looking to streamline its operations and increase efficiencies through the implementation of a restructuring program. The company’s restructuring program includes initiatives like streamlining of operations, shutting down of facilities, and workforce reduction. Biogen is also focusing its development efforts on neurology and biologics. First quarter revenues increased 9% to $1.20 billion, with MS drugs, Tysabri and Avonex being the primary growth drivers. Revenues were above the Zacks ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/04/26/biib-biogen-idec-earnings-above-estimates-on-multiple-sclerosis-drugs/72234/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(GSK) GlaxoSmithKline and Valeant Pharmaceuticals Respond to CRL From FDA</title>
		<link>http://www.stockbloghub.com/2011/04/26/gsk-glaxosmithkline-and-valeant-pharmaceuticals-respond-to-crl-from-fda/72377</link>
		<comments>http://www.stockbloghub.com/2011/04/26/gsk-glaxosmithkline-and-valeant-pharmaceuticals-respond-to-crl-from-fda/72377#comments</comments>
		<pubDate>Tue, 26 Apr 2011 15:34:08 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Champion Industries Inc]]></category>
		<category><![CDATA[CHMP]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[Valeant Pharmaceuticals International]]></category>
		<category><![CDATA[VRX]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=72377</guid>
		<description><![CDATA[GlaxoSmithKline (GSK) and Valeant Pharmaceuticals (VRX) recently submitted a response to the Complete Response Letter (CRL) received from the US Food and Drug Administration (FDA) for their epilepsy candidate, ezogabine. The CRL, which was issued in Nov 2010, was for non-clinical reasons. We note that earlier, in August 2010, Glaxo and Valeant had received a positive recommendation from an FDA advisory panel regarding ezogabine. The FDA’s Peripheral and Central Nervous System Drugs Advisory Committee had reviewed the safety and efficacy of the drug and voted unanimously in favor of ezogabine’s efficacy for the treatment of partial-onset seizures in adults where other treatments failed. However, later during the month, the FDA extended the review date for the candidate by three months. Approved in the EU Meanwhile, Glaxo and Valeant announced that ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/04/26/gsk-glaxosmithkline-and-valeant-pharmaceuticals-respond-to-crl-from-fda/72377/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(BIIB) Biogen Idec Earnings Report Beats The Street</title>
		<link>http://www.stockbloghub.com/2011/04/23/biib-biogen-idec-earnings-report-beats-the-street/72122</link>
		<comments>http://www.stockbloghub.com/2011/04/23/biib-biogen-idec-earnings-report-beats-the-street/72122#comments</comments>
		<pubDate>Sat, 23 Apr 2011 15:25:39 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[BIIB]]></category>
		<category><![CDATA[Biogen Idec Inc]]></category>
		<category><![CDATA[Champion Industries Inc]]></category>
		<category><![CDATA[CHMP]]></category>
		<category><![CDATA[Elan Corporation plc]]></category>
		<category><![CDATA[ELN]]></category>
		<category><![CDATA[Morgan Stanley]]></category>
		<category><![CDATA[MS]]></category>
		<category><![CDATA[Novartis AG]]></category>
		<category><![CDATA[NVS]]></category>
		<category><![CDATA[PIMCO Municipal Income Fund II]]></category>
		<category><![CDATA[PML]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>
		<category><![CDATA[TEVA]]></category>
		<category><![CDATA[Teva Pharmaceutical Industries Limited]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=72122</guid>
		<description><![CDATA[Biogen Idec (BIIB) reported first-quarter earnings per share of $1.42, 3 cents above the Zacks Consensus Estimate of $1.39 and well above the year-earlier figure of $1.04. Excluding the impact of stock-based compensation expense, first quarter 2011 earnings came in at $1.43 per share. Performance was boosted by higher mutliple sclerosis (MS) drug revenues, lower costs and lower share count. Biogen has been looking to streamline its operations and increase efficiencies through the implementation of a restructuring program. The company’s restructuring program includes initiatives like streamlining of operations, shutting down of facilities, and workforce reduction. Biogen is also focusing its development efforts on neurology and biologics. First quarter revenues increased 9% to $1.20 billion, with MS drugs, Tysabri and Avonex being the primary growth drivers. Revenues were above the Zacks ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/04/23/biib-biogen-idec-earnings-report-beats-the-street/72122/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(AMLN) Amylin Pharmaceuticals Reports Earnings Loss In-Line with Estimates</title>
		<link>http://www.stockbloghub.com/2011/04/20/amln-amylin-pharmaceuticals-reports-earnings-loss-in-line-with-estimates/71977</link>
		<comments>http://www.stockbloghub.com/2011/04/20/amln-amylin-pharmaceuticals-reports-earnings-loss-in-line-with-estimates/71977#comments</comments>
		<pubDate>Wed, 20 Apr 2011 21:35:47 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Alkermes Inc.]]></category>
		<category><![CDATA[ALKS]]></category>
		<category><![CDATA[AMLN]]></category>
		<category><![CDATA[Amylin Pharmaceuticals Inc]]></category>
		<category><![CDATA[Champion Industries Inc]]></category>
		<category><![CDATA[CHMP]]></category>
		<category><![CDATA[CMC]]></category>
		<category><![CDATA[Commercial Metals Company]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[LLY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=71977</guid>
		<description><![CDATA[Amylin Pharmaceuticals (AMLN) reported a net loss of 24 cents per share in the first quarter of 2011, in line with the Zacks Consensus Estimate and 3 cents below the year-ago loss of 27 cents. Despite a decline in revenues, year-over-year loss declined due to lower expenses. First quarter revenues declined 12.3% to $152.7 million. Revenues also missed the Zacks Consensus Estimate of $155 million. Quarterly Details Total revenues for the quarter declined 12.3% mainly due to lower net product sales. Quarterly revenues consisted of $150.8 million in product sales (down 12.5%) and $1.9 million in collaborative revenues, which consist of the amortization of upfront fees received under the company&#8217;s collaboration agreements with Eli Lilly (LLY) and Takeda. Product revenues comprised $128 million in sales of Byetta (exenatide) and $22.8 ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/04/20/amln-amylin-pharmaceuticals-reports-earnings-loss-in-line-with-estimates/71977/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(AMLN) Amylin Pharmaceuticals, Eli Lilly, and Alkermes Get Positive Opinion for Bydureon</title>
		<link>http://www.stockbloghub.com/2011/04/18/amln-amylin-pharmaceuticals-eli-lilly-and-alkermes-get-positive-opinion-for-bydureon/71813</link>
		<comments>http://www.stockbloghub.com/2011/04/18/amln-amylin-pharmaceuticals-eli-lilly-and-alkermes-get-positive-opinion-for-bydureon/71813#comments</comments>
		<pubDate>Tue, 19 Apr 2011 03:32:34 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Alkermes Inc.]]></category>
		<category><![CDATA[ALKS]]></category>
		<category><![CDATA[AMLN]]></category>
		<category><![CDATA[Amylin Pharmaceuticals Inc]]></category>
		<category><![CDATA[Champion Industries Inc]]></category>
		<category><![CDATA[CHMP]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[LLY]]></category>
		<category><![CDATA[Novo Nordisk A-S]]></category>
		<category><![CDATA[NVO]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=71813</guid>
		<description><![CDATA[Amylin Pharmaceuticals, Inc. (AMLN) and its partners, Eli Lilly and Company (LLY), and Alkermes, Inc. (ALKS), recently received good news regarding their pipeline candidate, Bydureon (exenatide once-weekly). Amylin, Eli Lilly and Alkermes said that Bydureon received a positive opinion from the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP). The CHMP issued an opinion in favor of approving Bydureon for the treatment of type II diabetes in combination with certain oral therapies. A final decision regarding the approvability of Bydureon should be delivered by the European Commission in 2-3 months. Approval would make Bydureon the first once-weekly type II diabetes treatment in the EU. The positive EU recommendation comes as a relief for Amylin which has recently been at the receiving end of a series of ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/04/18/amln-amylin-pharmaceuticals-eli-lilly-and-alkermes-get-positive-opinion-for-bydureon/71813/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(AMGN) Amgen Appeals EU Drug Opinion</title>
		<link>http://www.stockbloghub.com/2011/04/04/amgn-amgen-appeals-eu-drug-opinion/70440</link>
		<comments>http://www.stockbloghub.com/2011/04/04/amgn-amgen-appeals-eu-drug-opinion/70440#comments</comments>
		<pubDate>Mon, 04 Apr 2011 13:47:41 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Amgen Inc]]></category>
		<category><![CDATA[AMGN]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[Champion Industries Inc]]></category>
		<category><![CDATA[CHMP]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[LLY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=70440</guid>
		<description><![CDATA[Amgen (AMGN) is appealing the negative recommendation issued by the Committee for Medicinal Products for Human Use (CHMP) for the use of Vectibix plus chemotherapy in patients with wild-type KRAS metastatic colorectal cancer (mCRC). The company has requested the European Medicines Agency (EMA) to re-examine CHMP’s opinion. Negative Opinion Issued in March 2011 The CHMP had adopted a negative opinion regarding Amgen’s marketing authorization application for Vectibix’s label expansion in March 2011. At that time, Amgen had said that it would appeal the opinion. Results from two studies (PRIME and ‘181) showed that Vectibix plus chemotherapy improved progression-free survival in patients with wild-type KRAS mCRC compared to only chemotherapy. Moreover, Amgen reported a higher response rate in the Vectibix arm compared to chemotherapy alone. Amgen is looking to drive Vectibix sales ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/04/04/amgn-amgen-appeals-eu-drug-opinion/70440/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(GILD) Gilead Sciences Files Marketing Authorization Application for HIV Drug</title>
		<link>http://www.stockbloghub.com/2010/09/08/gild-gilead-sciences-files-marketing-authorization-application-for-hiv-drug/50720</link>
		<comments>http://www.stockbloghub.com/2010/09/08/gild-gilead-sciences-files-marketing-authorization-application-for-hiv-drug/50720#comments</comments>
		<pubDate>Wed, 08 Sep 2010 18:19:48 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[Champion Industries Inc]]></category>
		<category><![CDATA[CHMP]]></category>
		<category><![CDATA[GILD]]></category>
		<category><![CDATA[Gilead Sciences Inc]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=50720</guid>
		<description><![CDATA[Gilead Sciences Inc. (GILD) recently announced that it has submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) seeking approval for its once daily, single tablet, fixed dose combination of Truvada and TMC278 (rilpivirine) as a HIV treatment for adult patients. The MAA will first be reviewed by the Committee for Medicinal Products for Human Use (CHMP) and, based on the CHMP’s opinion, the EMA will deliver its decision regarding the approval of the drug. Truvada is a fixed dose, once daily tablet containing Viread and Emtriva, both manufactured by Gilead, and marketed for the treatment of HIV, while TMC278 is being developed by Tibotec Pharmaceuticals, which is a subsidiary of Johnson &#38; Johnson (JNJ), for treatment-naïve HIV infected adults. Gilead entered into an agreement with Tibotec ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/09/08/gild-gilead-sciences-files-marketing-authorization-application-for-hiv-drug/50720/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(SHPGY) Shire plc Hears Good News From European Medicines Agency</title>
		<link>http://www.stockbloghub.com/2010/07/11/shpgy-shire-plc-hears-good-news-from-european-medicines-agency/41791</link>
		<comments>http://www.stockbloghub.com/2010/07/11/shpgy-shire-plc-hears-good-news-from-european-medicines-agency/41791#comments</comments>
		<pubDate>Sun, 11 Jul 2010 14:23:59 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Champion Industries Inc]]></category>
		<category><![CDATA[CHMP]]></category>
		<category><![CDATA[GENZ]]></category>
		<category><![CDATA[Genzyme Corporation]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[PLX]]></category>
		<category><![CDATA[Protalix BioTherapeutics Inc]]></category>
		<category><![CDATA[Shire Limited]]></category>
		<category><![CDATA[SHPGY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=41791</guid>
		<description><![CDATA[Recently Shire plc (SHPGY) announced that its Gaucher disease product VPRIV (velaglucerase alfa) has received a favorable opinion from the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP). The committee recommended the approval of the enzyme replacement therapy for treating type I Gaucher disease. Furthermore, the drug has been granted accelerated assessment by the EMA in the European Union (EU) and enjoys orphan drug status from the Committee for Orphan Medical Products. Shire should be in a position to launch Vpriv in the EU by year end. Meanwhile, product launch in other countries should commence in 2011. Vpriv is already available in the U.S. where it received approval from the U.S. Food and Drug Administration (FDA) in late February 2010. Vpriv Could Eat into Cerezyme’s Market ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/07/11/shpgy-shire-plc-hears-good-news-from-european-medicines-agency/41791/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ALXN) Alexion Pharmaceutical&#8217;s Plant Gets Positive Opinion</title>
		<link>http://www.stockbloghub.com/2009/12/04/alxn-alexion-pharmaceuticals-plant-gets-positive-opinion/22023</link>
		<comments>http://www.stockbloghub.com/2009/12/04/alxn-alexion-pharmaceuticals-plant-gets-positive-opinion/22023#comments</comments>
		<pubDate>Sat, 05 Dec 2009 01:58:58 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Alexion Pharmaceuticals Inc]]></category>
		<category><![CDATA[ALXN]]></category>
		<category><![CDATA[Champion Industries Inc]]></category>
		<category><![CDATA[CHMP]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=22023</guid>
		<description><![CDATA[Alexion Pharmaceutical’s (ALXN) Rhode Island manufacturing facility (ARIMF) should be up and running shortly as a second source of supply for the drug Soliris (eculizumab). The company recently received good news with the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency issuing a positive opinion related to the final approval of the facility by the European Commission, which is expected in early 2010. Soliris, Alexion’s only US Food and Drug Administration (FDA) approved (approval received in March 2007) product, is a humanized monoclonal antibody complement inhibitor used for the treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH), a rare genetic blood disorder. Alexion also announced its intention to seek FDA approval for this facility. The company will meet with the FDA to provide additional information, and to ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/12/04/alxn-alexion-pharmaceuticals-plant-gets-positive-opinion/22023/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(SHPGY) Shire Plc&#8217;s Drug Seeks European Medicines Agency Approval</title>
		<link>http://www.stockbloghub.com/2009/11/25/shpgy-shire-plcs-drug-seeks-european-medicines-agency-approval/21289</link>
		<comments>http://www.stockbloghub.com/2009/11/25/shpgy-shire-plcs-drug-seeks-european-medicines-agency-approval/21289#comments</comments>
		<pubDate>Wed, 25 Nov 2009 18:10:48 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Champion Industries Inc]]></category>
		<category><![CDATA[CHMP]]></category>
		<category><![CDATA[GENZ]]></category>
		<category><![CDATA[Genzyme Corporation]]></category>
		<category><![CDATA[MAA]]></category>
		<category><![CDATA[Mid-America Apartment Communities Inc]]></category>
		<category><![CDATA[PLX]]></category>
		<category><![CDATA[Protalix BioTherapeutics Inc]]></category>
		<category><![CDATA[Shire Limited]]></category>
		<category><![CDATA[SHPGY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=21289</guid>
		<description><![CDATA[Shire plc (SHPGY) continues to make progress with its Gaucher disease candidate, velaglucerase alfa. The company recently submitted a marketing authorization application (MAA) to the European Medicines Agency (EMEA) for velaglucerase alfa for the treatment of type I Gaucher disease. The company has already asked for approval in other markets like the U.S. and Canada. Shire is seeking an accelerated review of the MAA. Given the shortage in supply of Genzyme’s (GENZ) Cerezyme, which is the leader in the treatment of patients with Gaucher disease, the Committee for Medicinal Products for Human Use (CHMP) has accepted Shire’s request. Accordingly, the review time has been reduced by 60 days to 150 days with the review scheduled to commence in December. Once approved and launched commercially, velaglucerase alfa will compete directly with ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/11/25/shpgy-shire-plcs-drug-seeks-european-medicines-agency-approval/21289/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(MRK) Positive Opinion for Merck Drug From European Medicines Agency</title>
		<link>http://www.stockbloghub.com/2009/11/23/mrk-positive-opinion-for-merck-drug-from-european-medicines-agency/21147</link>
		<comments>http://www.stockbloghub.com/2009/11/23/mrk-positive-opinion-for-merck-drug-from-european-medicines-agency/21147#comments</comments>
		<pubDate>Tue, 24 Nov 2009 05:56:01 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Champion Industries Inc]]></category>
		<category><![CDATA[CHMP]]></category>
		<category><![CDATA[Merck & Company Inc]]></category>
		<category><![CDATA[MRK]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=21147</guid>
		<description><![CDATA[Merck (MRK) announced that the European Medicines Agency’s (EMEA) Committee for Medicinal Products for Human Use (CHMP) has recommended approval of Elonva (corifollitropin alfa injection). Merck is seeking the drug’s approval as a treatment in controlled ovarian stimulation (COS) in combination with a GnRH antagonist for the development of multiple follicles in women who have participated in an assisted reproductive technology (ART) program. On European Commission’s approval, Merck would be able to market Elonva with unified labeling valid in all European Union Member States. Elonva is the first in a class of sustained follicle stimulants (SFS). It scores better than the current available treatment option ? a single subcutaneous injection of Elonva is likely to replace the first seven injections of any daily recombinant follicle stimulating hormone (rFSH) preparation in ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/11/23/mrk-positive-opinion-for-merck-drug-from-european-medicines-agency/21147/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(NVS) FDA Delays Novartis AG Treatment</title>
		<link>http://www.stockbloghub.com/2009/10/20/nvs-fda-delays-novartis-ag-treatment/18131</link>
		<comments>http://www.stockbloghub.com/2009/10/20/nvs-fda-delays-novartis-ag-treatment/18131#comments</comments>
		<pubDate>Tue, 20 Oct 2009 20:15:39 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[AstraZeneca plc]]></category>
		<category><![CDATA[AZN]]></category>
		<category><![CDATA[Champion Industries Inc]]></category>
		<category><![CDATA[Charles River Laboratories International Inc]]></category>
		<category><![CDATA[CHMP]]></category>
		<category><![CDATA[CRL]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[Novartis AG]]></category>
		<category><![CDATA[NVS]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=18131</guid>
		<description><![CDATA[Recently, Novartis AG (NVS) announced that it has received a Complete Response Letter (CRL) for QAB149 (indacaterol) ? a bronchodilator for the treatment of adults suffering from chronic obstructive pulmonary disease (COPD) ? from the US Food and Drug Administration (FDA). The US agency has asked for additional information on the proposed dosing of the drug. Novartis had filed for the US approval of the drug in December last year. Last month, the Committee for Medicinal Products for Human Use (CHMP) recommended the approval of QAB149 in the European Union to treat COPD patients as a once-daily therapy with two doses (150 micrograms and 300 micrograms). The positive opinion from the CHMP is a boost to Novartis as it aims to be a strong player in the field of respiratory ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/10/20/nvs-fda-delays-novartis-ag-treatment/18131/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(MRK) Mixed News for Merck Drug</title>
		<link>http://www.stockbloghub.com/2009/10/03/mrk-mixed-news-for-merck-drug/16330</link>
		<comments>http://www.stockbloghub.com/2009/10/03/mrk-mixed-news-for-merck-drug/16330#comments</comments>
		<pubDate>Sat, 03 Oct 2009 22:59:50 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[AMLN]]></category>
		<category><![CDATA[Amylin Pharmaceuticals Inc]]></category>
		<category><![CDATA[Champion Industries Inc]]></category>
		<category><![CDATA[CHMP]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[LLY]]></category>
		<category><![CDATA[Merck & Company Inc]]></category>
		<category><![CDATA[MRK]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com.php5-2.dfw1-2.websitetestlink.com/?p=16330</guid>
		<description><![CDATA[Last week, Merck (MRK) received a favorable opinion from the European Medicines Agency&#8217;s (EMEA) Committee for Medicinal Products for Human Use (CHMP) for its diabetes drugs Januvia (sitagliptin) and Janumet (sitagliptin and metformin). The committee recommended the drugs to be used as add-ons to insulin for the treatment of type 2 diabetes. In the US, a supplemental New Drug Application (sNDA) for the use of Januvia and Janumet in combination with insulin has been accepted by the FDA and is currently under review. While the favorable opinion from the committee is good news, we remain concerned about the risk of inflamed pancreas for patients treated with Januvia or Janumet. Although the company officials refuse to accept the link, the FDA has stated that 88 cases of acute pancreatitis Incorporatedluding two ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/10/03/mrk-mixed-news-for-merck-drug/16330/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>

